2014

Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)

 

 

NEW YORK, Oct. 22, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)
http://www.reportlinker.com/p01020573/Ophthalmology-Therapeutics-Market-to-2018---Dosing-Convenience-and-Cost-effectiveness-Continue-to-Drive-Eylea's-Prescription-Share-in-Wet-Age-Related-Macular-Degeneration-Wet-AMD.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)", which provides insights into the global ophthalmology therapeutics market, with forecasts until 2018. The report provides an in-depth analysis of the key therapeutic indications of ophthalmology, namely glaucoma, allergic conjunctivitis, Dry Eye Syndrome (DES), Diabetic Macular Edema (DME), and Wet Age Macular Degeneration (Wet-AMD). The report also examines the ophthalmology therapeutics treatment usage patterns for the covered indications. In addition, the report includes insights into the ophthalmology R&D pipeline.

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

In 2011, the global ophthalmology therapeutics market was estimated to be around $10 billion, growing at a Compound Annual Growth Rate (CAGR) of 7.2% between 2004 and 2011. The glaucoma market was the largest segment followed by Wet-AMD. These segments accounted for 36% and 32% of the global ophthalmology therapeutics market in 2011, respectively. The decline in glaucoma revenue due to significant generic erosion will change the therapeutic landscape until 2018, when glaucoma is expected to account for 23%, a decline of 13% relative to 2011, and the wet-AMD market is expected to account for 37% of the global ophthalmology market, an increase of 5% relative to 2011. The decline in the glaucoma market is expected to be offset by a healthy growth in the wet-AMD, DME, and DES markets. These markets are expected to grow due to the presence of considerable unmet need and increasing treatment-seeking and diagnosis rates.

The top pharmaceutical companies in the ophthalmology market are Pfizer Inc., Allergan Inc., Alcon Inc, Novartis AG., Merck & co. Inc and Roche. Approximately 70% of the market is covered by these six companies.

Scope

- The report analyzes treatment usage patterns, market characterization, pipeline analysis, competitive landscape and key M&A trends in the glaucoma, allergic conjunctivitis, DES, DME, and wet-AMD therapeutics market.
- Data and analysis for the global ophthalmology therapeutics market
- Annualized market data for the ophthalmology therapeutics market from 2004 to 2011, with forecasts to 2018
- Key drivers and restraints that have had a significant impact on the market
- The competitive landscape of the global ophthalmology therapeutics market
- Key M&A activities and licensing agreements that took place in the ophthalmology therapeutics market

Reasons to buy

- Align your product portfolio to the markets with high growth potential
- Develop market entry and market expansion strategies by identifying the potential regions and therapeutic segments poised for strong growth
- Devise a more effectively tailored country strategy through the understanding of key drivers and barriers in the ophthalmology market
- Develop key strategic initiatives by understanding the key focus areas and leading companies
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships



1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 11
2 Global Ophthalmology Therapeutics Market - Introduction 13
2.1 Overview 13
3 Global Ophthalmology Therapeutics Market - Market Overview 14
3.1 Introduction 14
3.2 Revenue 15
3.3 Annual Cost of Treatment 17
3.4 Treatment Usage Pattern 18
3.5 Branded and Generic Market Share 19
4 Global Ophthalmology Therapeutics Market - Geographical Landscape 20
4.1 Geographical Break-up 20
4.1.1 The US 20
4.1.2 Top Five Countries in Europe 24
4.1.3 Japan 29
5 Global Ophthalmology Therapeutics Market - Therapeutic Landscape 33
5.1 Glaucoma Therapeutics Market 33
5.1.1 Introduction 33
5.1.2 Revenue 38
5.1.3 Annual Cost of Treatment 40
5.1.4 Treatment Usage Pattern 41
5.1.5 Treatment Flow Algorithm 43
5.1.6 Branded and Generic Market Share 44
5.1.7 Drivers for the Glaucoma Therapeutics Market 45
5.1.8 Restraints for Glaucoma Therapeutics Market 45
5.1.9 Geographical Segmentation 46
5.2 Allergic Conjunctivitis Therapeutics Market 47
5.2.1 Introduction 47
5.2.2 Revenue 49
5.2.3 Annual Cost of Treatment 50
5.2.4 Treatment Usage Pattern 51
5.2.5 Treatment Flow Algorithm 53
5.2.6 Branded and Generic Market Share 54
5.2.7 Geographical Segmentation 55
5.3 Wet Age Macular Degeneration Therapeutics Market 56
5.3.1 Introduction 56
5.3.2 Revenue 59
5.3.3 Annual Cost of Treatment 61
5.3.4 Treatment Usage Pattern 62
5.3.5 Treatment Flow Algorithm 64
5.3.6 Branded and Generic Market Share 65
5.3.7 Drivers for Wet Age-related Macular Degeneration Therapeutics Market 65
5.3.8 Restraints for Wet Age-Related Macular Degeneration Therapeutics Market 66
5.3.9 Geographical Segmentation 66
5.4 Diabetic Macular Edema Therapeutics Market 68
5.4.1 Introduction 68
5.4.2 Revenue 70
5.4.3 Annual Cost of Treatment 71
5.4.4 Treatment Usage Pattern 72
5.4.5 Treatment Flow Algorithm 74
5.4.6 Drivers for Diabetic Macular Edema Therapeutics Market 74
5.4.7 Restraints for Diabetic Macular Edema Therapeutics Market 75
5.4.8 Geographical Segmentation 75
5.5 Dry Eye Syndrome, Therapeutics Market 76
5.5.1 Introduction 76
5.5.2 Revenue 77
5.5.3 Annual Cost of Treatment 78
5.5.4 Treatment Usage Pattern 79
5.5.5 Treatment Flow Algorithm 80
5.5.6 Branded and Generic Market Share 81
5.5.7 Drivers for Dry Eye Syndrome Therapeutics Market 81
5.5.8 Restraints for Dry Eye Syndrome Therapeutics Market 81
5.5.9 Geographical Segmentation 82
6 Global Ophthalmology Therapeutics Market - APAC 84
6.1 India 84
6.1.1 Overview 84
6.1.2 Key Trends 84
6.1.3 Key Strategies 85
6.2 China 86
6.2.1 Overview 86
6.2.2 Key Trends 86
6.2.3 Key Strategies 87
6.3 Australia 88
6.3.1 Overview 88
6.3.2 Pricing and Reimbursement 88
7 Global Ophthalmology Therapeutics Market - Profiles of Promising Pipeline Products 89
7.1 Iluvien (fluocinolone acetonide) 89
7.1.1 Overview 89
7.1.2 Efficacy 89
7.1.3 Safety 89
7.1.4 Clinical Study Details 89
7.2 Rebamipide (OPC-12759E) 90
7.2.1 Overview 90
7.2.2 Clinical Details 90
7.3 Remura (bromfenac) 90
7.3.1 Overview 90
7.3.2 Clinical details 90
7.4 Ozurdex (dexamethasone) 90
7.4.1 Overview 90
7.4.2 Clinical Details 90
7.5 ISTA -Ecabet Sodium 91
7.5.1 Overview 91
7.6 Allergan's Androgen Tear 91
7.6.1 Overview 91
8 Global Ophthalmology Therapeutics Market - Competitive Landscape 92
8.1 Allergan, Inc. 92
8.1.1 Business Overview 92
8.1.2 SWOT 92
8.2 Merck & Co Inc 93
8.2.1 Introduction 93
8.2.2 SWOT 93
8.3 Novartis AG 94
8.3.1 Introduction 94
8.3.2 SWOT 95
8.4 Pfizer 95
8.4.1 Business Description 95
8.4.2 SWOT 96
8.5 Roche 96
8.5.1 Introduction 96
8.5.2 SWOT 96
9 Global Ophthalmology Therapeutics Market - Strategic Consolidations 97
9.1 Mergers and Acquisitions 97
9.1.1 Introduction 97
9.1.2 Key Mergers and Acquisitions Deals 97
9.1.3 Segmentation by Geography 98
9.1.4 Segmentation by Deal Value 99
9.2 Co-development Deals 100
9.2.1 Major Co-development Deals 100
9.2.2 Segmentation by Geography 100
9.3 Licensing Deals 101
9.3.1 Major Licensing Deals 101
9.3.2 Segmentation by Geography 101
9.3.3 Segmentation by Value 102
10 Global Ophthalmology Therapeutics Market - Appendix 103
10.1 Market Definitions 103
10.2 Abbreviations 103
10.3 Bibliography 105
10.4 Research Methodology 106
10.4.1 Coverage 106
10.4.2 Secondary Research 106
10.4.3 Primary Research 107
10.5 Therapeutic Landscape 107
10.5.2 Market Size by Geography 110
10.6 Geographical Landscape 111
10.7 Pipeline Analysis 111
10.8 Competitive Landscape 111
10.8.1 Expert Panel Validation 111
10.9 Contact Us 111
10.10 Disclaimer 111

1.1 List of Tables

Table 1: Ophthalmology Market, Global, Revenue, ($bn), 2004–2011 16
Table 2: Ophthalmology Market, Global, Revenue, ($bn), 2011–2018 16
Table 3: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2004–2011 17
Table 4: Ophthalmology Market, Global, Annual Cost of Treatment, ($), 2011–2018 17
Table 5: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004–2011 18
Table 6: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2011–2018 18
Table 7: Ophthalmology Market, the US, Revenue ($bn), 2004–2011 20
Table 8: Ophthalmology Market, the US, Revenue ($bn), 2011–2018 20
Table 9: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004–2011 21
Table 10: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2011–2018 21
Table 11: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004–2011 22
Table 12: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2011–2018 22
Table 13: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004–2011 24
Table 14: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2011–2018 25
Table 15: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment, ($), 2004–2011 26
Table 16: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2011–2018 26
Table 17: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004–2011 27
Table 18: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2011–2018 28
Table 19: Ophthalmology Market, Japan, Revenue ($m), 2004–2011 29
Table 20: Ophthalmology Market, Japan, Revenue ($m), 2011–2018 29
Table 21: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004–2011 30
Table 22: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2011–2018 30
Table 23: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004–2011 31
Table 24: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2011–2018 32
Table 25: Ophthalmology Market to 2018, Major Types of Glaucoma 33
Table 26: Ophthalmology Market to 2018, Mechanism of Action of Key Glaucoma Medications 35
Table 27: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004–2011 38
Table 28: Ophthalmology Market to 2018, Global, Glaucoma, Revenue Forecast ($bn), 2011–2018 38
Table 29: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004–2011 40
Table 30: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2011–2018 40
Table 31: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004–2011 41
Table 32: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2011–2018 41
Table 33: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004–2011 46
Table 34: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2011–2018 47
Table 35: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004–2011 49
Table 36: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2011–2018 49
Table 37: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004–2011 50
Table 38: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2011–2018 50
Table 39: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004–2011 51
Table 40: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2011–2018 52
Table 41: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004–2011 55
Table 42: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2011–2018 56
Table 43: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004–2011 59
Table 44: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2011–2018 60
Table 45: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004–2011 61
Table 46: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2011–2018 61
Table 47: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2004–2011 62
Table 48: Ophthalmology Market to 2018, Global, Wet-Age Related Macular Degeneration, Treatment Usage Pattern (million), 2011–2018 62
Table 49: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004–2011 67
Table 50: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2011–2018 67
Table 51: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011–2018 70
Table 52: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011–2018 71
Table 53: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern ('000), 2011–2018 72
Table 54: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011–2018 75
Table 55: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004–2011 77
Table 56: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2011–2018 77
Table 57: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004–2011 78
Table 58: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2011–2018 78
Table 59: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004–2011 79
Table 60: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2011–2018 80
Table 61: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004–2011 82
Table 62: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2011–2018 83
Table 63: Ophthalmology Market to 2018, PBS Reimbursement List, Australia, 2012 88
Table 64: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012 98
Table 65: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009– 2012 99
Table 66: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012 100
Table 67: Ophthalmology Market to 2018, Global, Number of Deals by Geography, 2009– 2012 101
Table 68: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value ($m), 2009– 2012 102

1.2 List of Figures

Figure 1: Ophthalmology Market to 2018, Global, Revenue, ($bn), 2004–2018 15
Figure 2: Ophthalmology Market to 2018, Global, Annual Cost of Treatment, ($), 2004–2018 17
Figure 3: Ophthalmology Market, Global, Treatment Usage Patterns (million), 2004–2018 18
Figure 4: Ophthalmology Market to 2018, Global, Branded and Generic Market Share (%), 2011 and 2018 19
Figure 5: Ophthalmology Market, the US, Revenue ($bn), 2004–2018 20
Figure 6: Ophthalmology Market, the US, Annual Cost of Treatment ($), 2004–2018 21
Figure 7: Ophthalmology Market, the US, Treatment Usage Pattern (million), 2004–2018 22
Figure 8: Ophthalmology Market, Top Five Countries of Europe, Revenue ($m), 2004–2018 24
Figure 9: Ophthalmology Market, Top Five Countries of Europe, Annual Cost of Treatment ($), 2004–2018 26
Figure 10: Ophthalmology Market, Top Five Countries of Europe, Treatment Usage Pattern (million), 2004–2018 27
Figure 11: Ophthalmology Market, Japan, Revenue ($m), 2004–2018 29
Figure 12: Ophthalmology Market, Japan, Annual Cost of Treatment ($), 2004–2018 30
Figure 13: Ophthalmology Market, Japan, Treatment Usage Pattern (million), 2004–2018 31
Figure 14: Ophthalmology Market to 2018, Global, Glaucoma, Revenue ($bn), 2004–2018 38
Figure 15: Ophthalmology Market to 2018, Global, Glaucoma, Annual Cost of Therapy ($), 2004–2018 40
Figure 16: Ophthalmology Market to 2018, Global, Glaucoma, Treatment Usage Pattern (million), 2004–2018 41
Figure 17: Ophthalmology Market to 2018, Glaucoma, Treatment Flow Algorithm 43
Figure 18: Ophthalmology Market to 2018, Glaucoma Market, Global, Branded and Generic Market Share (%), 2011 and 2018 44
Figure 19: Ophthalmology Market to 2018, Global, Glaucoma, Geographical Segmentation of Revenues ($m), 2004–2018 46
Figure 20: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Revenue ($m), 2004–2018 49
Figure 21: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Annual Cost of Therapy ($), 2004–2018 50
Figure 22: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Treatment Usage Pattern (million), 2004–2018 51
Figure 23: Ophthalmology Market to 2018, Allergic Conjunctivitis, Global, Treatment Flow Algorithm 53
Figure 24: Ophthalmology Market to 2018, Branded and Generic Market Share (%), 2011 and 2018 54
Figure 25: Ophthalmology Market to 2018, Global, Allergic Conjunctivitis, Geographical Segmentation of Revenues ($m), 2004–2018 55
Figure 26: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, Revenue ($bn), 2004–2018 59
Figure 27: Ophthalmology Market to 2018, Global, Wet Age Related Macular Degeneration, ACT ($), 2004–2018 61
Figure 28: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Treatment Usage Pattern (million), 2004–2018 62
Figure 29: Ophthalmology Market to 2018, Wet Age-Related Macular Degeneration, Global, Treatment Flow Algorithm 64
Figure 30: Ophthalmology Market to 2018, Wet-Age Related Macular Degeneration, Global, Branded and Generic Market Share (%), 2011–2018 65
Figure 31: Ophthalmology Market to 2018, Global, Wet Age-Related Macular Degeneration, Geographical Segmentation of Revenues ($m), 2004–2018 66
Figure 32: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Revenue ($m), 2011–2018 70
Figure 33: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Annual Cost of Therapy ($), 2011–2018 71
Figure 34: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Treatment Usage Pattern ('000), 2004–2018 72
Figure 35: Ophthalmology Market to 2018, Diabetic Macular Edema, Global, Treatment Flow Algorithm 74
Figure 36: Ophthalmology Market to 2018, Global, Diabetic Macular Edema, Geographical Segmentation of Revenues ($m), 2011–2018 75
Figure 37: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Revenue ($bn), 2004–2018 77
Figure 38: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Annual Cost of Therapy ($), 2004–2018 78
Figure 39: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Treatment Usage Pattern (million), 2004–2018 79
Figure 40: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Treatment Flow Algorithm, 2011 80
Figure 41: Ophthalmology Market to 2018, Dry Eye Syndrome, Global, Branded and Generic Market Share (%), 2011–2018 81
Figure 42: Ophthalmology Market to 2018, Global, Dry Eye Syndrome, Geographical Segmentation of Revenues ($m), 2004–2018 82
Figure 43: Ophthalmology Market to 2018, Allergan, SWOT, 2012 92
Figure 44: Ophthalmology Market to 2018, Merck Co & Inc, SWOT, 2012 93
Figure 45: Ophthalmology Market to 2018, Novartis AG, SWOT, 2012 95
Figure 46: Ophthalmology Market to 2018, Pfizer, SWOT, 2012 96
Figure 47: Ophthalmology Market to 2018, Roche, SWOT, 2012 96
Figure 48: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009– 2012 98
Figure 49: Ophthalmology Market to 2018, Global, Segmentation of Deals by Value (%),2009– 2012 99
Figure 50: Ophthalmology Market to 2018 Global, Number of Deals by Geography (%),2009– 2012 100
Figure 51: Ophthalmology Market to 2018, Global, Number of Deals by Geography (%), 2009– 2012 101
Figure 52: Ophthalmology Market to 2018, Global, Number of Deals by Deal Value (%), 2009– 2012 102
Figure 53: GBI Research Market Forecasting Model 110

Companies mentioned
Allergan, Inc.
Merck & Co Inc
Novartis AG
Pfizer
Roche





To order this report:
Therapy Industry:
Ophthalmology Therapeutics Market to 2018 - Dosing Convenience and Cost-effectiveness Continue to Drive Eylea's Prescription Share in Wet Age-Related Macular Degeneration (Wet-AMD)

__________________________
Contact Nicolas: nicolasbombourg@reportlinker.com
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.